{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-lymphoid+Malignancies&page=2",
    "query": {
      "condition": "B-lymphoid Malignancies",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-lymphoid+Malignancies&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T12:29:00.379Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00068523",
      "title": "Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "UV light therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 10,
      "start_date": "2003-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-07-27",
      "last_synced_at": "2026-07-24T12:29:00.379Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068523"
    },
    {
      "nct_id": "NCT00313079",
      "title": "Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Lymphocytic",
        "Leukemia",
        "Acute Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "MAb 216",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Steven E. Coutre",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2006-05",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2012-07-03",
      "last_synced_at": "2026-07-24T12:29:00.379Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00313079"
    },
    {
      "nct_id": "NCT05024045",
      "title": "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Lymphocytic, Chronic, B-Cell",
        "Lymphoma, B-cell Marginal Zone",
        "Lymphoma, Non-Hodgkin",
        "Multiple Myeloma",
        "B-cell Lymphoma",
        "Waldenstrom Macroglobulinemia",
        "Lymphoma, Mantle-Cell"
      ],
      "interventions": [
        {
          "name": "LOXO-338",
          "type": "DRUG"
        },
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2021-09-30",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-07-24T12:29:00.379Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05024045"
    },
    {
      "nct_id": "NCT03045328",
      "title": "Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Steven E. Coutre",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-09-26",
      "completion_date": "2021-08-05",
      "has_results": true,
      "last_update_posted_date": "2021-09-29",
      "last_synced_at": "2026-07-24T12:29:00.379Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Stanford, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03045328"
    },
    {
      "nct_id": "NCT04578600",
      "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma",
        "Recurrent Follicular Lymphoma",
        "Recurrent Hairy Cell Leukemia",
        "Recurrent Lymphoplasmacytic Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Mucosa-Associated Lymphoid Tissue Lymphoma",
        "Refractory Follicular Lymphoma",
        "Refractory Hairy Cell Leukemia",
        "Refractory Lymphoplasmacytic Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Oral Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Joseph Tuscano",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2020-10-23",
      "completion_date": "2025-02-21",
      "has_results": false,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-07-24T12:29:00.379Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04578600"
    },
    {
      "nct_id": "NCT02706392",
      "title": "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Mantle Cell Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Stage III Lung Non-Small Cell Cancer AJCC v7",
        "Stage IIIA Lung Non-Small Cell Cancer AJCC v7",
        "Stage IIIB Lung Non-Small Cell Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Lung Non-Small Cell Cancer AJCC v7",
        "Unresectable Lung Non-Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "ROR1 CAR-specific Autologous T-Lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2016-03-16",
      "completion_date": "2021-09-28",
      "has_results": true,
      "last_update_posted_date": "2022-08-31",
      "last_synced_at": "2026-07-24T12:29:00.379Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02706392"
    },
    {
      "nct_id": "NCT01787409",
      "title": "Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aggressive Non-Hodgkin Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-Cell Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Diffuse Large B-Cell Lymphoma",
        "Enteropathy-Associated T-Cell Lymphoma",
        "Hepatosplenic T-Cell Lymphoma",
        "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Nasal Type Extranodal NK/T-Cell Lymphoma",
        "Peripheral T-Cell Lymphoma, Not Otherwise Specified",
        "Primary Cutaneous Anaplastic Large Cell Lymphoma",
        "Refractory Anaplastic Large Cell Lymphoma",
        "Small Lymphocytic Lymphoma",
        "Subcutaneous Panniculitis-Like T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cholecalciferol",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 565,
      "start_date": "2013-03-06",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-07-24T12:29:00.379Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01787409"
    },
    {
      "nct_id": "NCT01069432",
      "title": "Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2010-05",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2018-03-19",
      "last_synced_at": "2026-07-24T12:29:00.379Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01069432"
    },
    {
      "nct_id": "NCT00049712",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "etaracizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "2002-10",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2019-12-13",
      "last_synced_at": "2026-07-24T12:29:00.379Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049712"
    },
    {
      "nct_id": "NCT05281809",
      "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-Cell Lymphoma",
        "B Acute Lymphoblastic Leukemia",
        "Diffuse Large B Cell Lymphoma",
        "Mantle Cell Lymphoma",
        "Follicular Lymphoma",
        "Marginal Zone Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Transformed Lymphoma"
      ],
      "interventions": [
        {
          "name": "Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Lister",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-04-19",
      "completion_date": "2037-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-13",
      "last_synced_at": "2026-07-24T12:29:00.379Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05281809"
    }
  ]
}